| Featured Programs
Malignant Fungating Wounds (MFW)
Program: VT1953 Gel Status: Clinical Development
Malignant fungating wounds estimated affect up to 5%-14% of advanced cancer patients worldwide, causing severe pain, malodor, and social isolation. There are currently no approved drugs—patients rely on suboptimal off-label treatments.
VT1953 is a first-in-class gel designed to:
- Target DNA-gyrase to reduce the bacterial drivers of malodor.
- Inhibit the TLR-MD2 inflammation pathway to decrease pain and inflammation.
With its dual mechanism and strong clinical rationale, VT1953 has the potential to dramatically improve the quality of life for cancer patients suffering from MFW, while pursuing an attractive orphan regulatory pathway. -----
Uveitis
Program: VT1908 Eye Drops Status: Preclinical Development
Uveitis is a leading cause of blindness, with current treatments dominated by steroids—yet many patients are non-responders or steroid-incompatible due to side effects and contraindications.
VT1908 is a novel sterile eye drop that:
- Inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme driving immune cell activity.
- Demonstrated comparable efficacy to steroids in preclinical uveitis models.
- Offers a promising alternative for patients who cannot tolerate existing therapies.
This program is advancing toward clinical development with the potential to redefine treatment standards in immune-related eye disease.
Grab Source And More Here: HIND Website. -----
Here's 5 Potential Catalysts We're Tracking For (Nasdaq: HIND)
#1. HIND Potential Catalyst - A Tiny Float Could Create A Serious Environment For Heightened Volatility Potential.
According to the Yahoo Finance website, HIND has a very low float.
In fact, the website reports this profile to have approximately 1.54Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the 2nd half of 2025, could it create a near term spark? -----
#2. HIND Potential Catalyst - Milestones Abound As Company Announces "Transformational" Q1 Following Nasdaq Listing.
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
(Quarter Ended September 30, 2025)
- Completed a streamlined Nasdaq listing, with a 100% common st-ock capital structure
- Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations.
- Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials.
- Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies.
- Launched AI strategy with the acquisition of MIT startup Oculo
CAMBRIDGE, Mass., November 18, 2025--(BUSINESS WIRE)--Vyome Holdings, Inc., ("Vyome") (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US–India innovation corridor, today announced its financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq.
This quarter marks Vyome’s first full reporting period as a newly listed Nasdaq company. Vyome is a clinical-stage, and AI-focused company positioned to accelerate development across immuno-inflammatory and potential orphan indications.
"Vyome is targeting one of the biggest challenges in the world today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure, the development of our assets, or looking at AI opp's," said Krishna Gupta, Chairman of Vyome. "We had a great first quarter as a public company thanks to our unique strengths, including expertise in/access to the US-India innovation corridor. We announced an important interim result for our drug targeting the Bn-dollar opp. in malignant fungating wound (MFW), and it’s just the beginning!"
"This quarter marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in our first quarter as a public company and strengthening our organization while advancing our lead program," noted Venkat Nelabhotla, CEO of Vyome. He further added, "The promising interim Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients."
...
Read the full article here. -----
#3. HIND Potential Catalyst - A Major Acquisition And A New Business Unit Highlight HIND's Disruptive Approach.
Vyome Holdings Acquires MIT AI Spinout Oculo Health
Launches business unit to create AI psychiatrist focused on reducing inflammation
Vyome remains fully funded through 2026 to unlock value from core assets
CAMBRIDGE, Mass., September 29, 2025--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology ("MIT"). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo’s assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Directors AI subcommittee comprised of Krishna Gupta, Mohanjit Jolly, and Stash Pomichter – all of whom are MIT alumni with deep AI expertise.
"Inflammation is currently one of the biggest health crises facing humanity, and we intend to attack the condition from all angles in order to limit the usage of steroids," said Stash Pomichter, a Director of Vyome. "We envision an AI psychiatrist that can diagnose and help treat systemic inflammation by targeting behavioral drivers and biomarkers."
"The goal is to establish an entirely new therapeutic category at the intersection of mental health, psychoneuroimmunology, and digital health, with global commercialization beginning in the US and India. The team at Oculo has developed an innovative foundation of software and research, including on biomarkers such as ‘brain burn’ that are quite relevant to our focus at Vyome, and we are excited to build on this foundation," added Pomichter.
...
"The market size for digital therapeutics, especially ones that can reduce the reliance on biologics or other drugs, could end up being greater than $100Bn over the next decade," said Mohanjit Jolly, a Director at Vyome and Partner at Iron Pillar, a firm with several AI related in-vest-ments in the US and India. "The advances in AI create an opp. to use data to better human lives across the board, but our focus is on reducing inflammation in every part of the body. It is one of the biggest health issues facing our society and leads to significant reliance on harmful drugs. I’m excited we were able to close this transaction with Oculo to launch our AI efforts in addition to advancing our existing inflammation-focused biotech assets."
Read the full article here. -----
#4. HIND Potential Catalyst - Strong Results From Preclinical Studies Investigating VT-1908 Could Start Generating Serious Buzz.
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3Bn Addressable Market Opp.
Vyome’s offering is a first-of-its-kind in a broader $20Bn potential addressable ocular inflammation market
VT-1908 eyedrop achieves the desired concentration in the anterior chamber of the eye and significantly reduces uveitis score in preclinical models (P<0.001)
CAMBRIDGE, Mass., September 17, 2025--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1).
Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States alone (2), making it a roughly $3Bn market opp. by 2032. Steroids are the first line of treatment for uveitis, but many patients do not respond, and steroid use causes major complications, including cataract and increased pressure in the eye, leading to glaucoma. There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need. The broader addressable global market to treat inflammation in the eye is expected to exceed $20Bn by 2030 (5).
In a preclinical model of anterior uveitis, the most common form of uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score. The efficacy of VT-1908 was found to be similar to a clinically used steroid (1).
"Inflammation is one of the biggest problems of our time, which is often linked to the immune system, and we are addressing the root cause in tangible and specific applications in the eye. The fact that VT-1908 is as effective as a steroid is exciting as we can aim to replace steroids in the eye, which are associated with a number of complications," said Dr. Shiladitya Sengupta, Co-Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. "A large number of patients cannot even use steroids, and our results offer hope that a breakthrough treatment is potentially on the horizon for such patients with uveitis. Our preclinical results support advancing VT-1908 into the clinics."
Venkat Nelabhotla, CEO of Vyome, stated, "We are excited with the preclinical efficacy signals. We expect to initiate Phase 1/2 clinical trial in the second half of 2026. While we will target uveitis in the near-term, the long-term goal is to replace steroids to treat ocular inflammation, which is a potential $20Bn (5) addressable market opportunity. We look forward to advancing this program as part of Vyome’s broader chronic immune-inflammation portfolio."
Read the full article here. -----
#5. HIND Potential Catalyst - A Maxim Group Analyst Tags HIND With A $15 Target.
The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.
Jason McCarthy, an analyst at Maxim Group covering the biotechnology sector, has suggested a $15.00 target for Vyome Holdings, Inc. as of 12/5/25 according to published info on the company’s website.
With this $15.00 target, there could be upside potential of over 150% for HIND from its closing valuation Friday. -----
Coverage on Vyome Holdings, Inc. (Nasdaq: HIND) is now officially underway.
Stay frosty and keep your eyes peeled for updates coming shortly. Talk soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 12/07/2025 and ending on 12/08/2025 to publicly disseminate information about (HIND:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (HIND:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/hind-wai94/#details | 
